Evidence map›Paper›PMID 39400627›Full record

ReviewMedical oncology (Northwood, London, England)2024

Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies.

Dixita Joshi, Janaki Patel, Muskaan Munshi, Zeel Mistry, Alok Prajapati, Asmi Mukherjee, A V Ramachandran, Nidarshana Chaturvedi Parashar, Gaurav Parashar, Shafiul Haque and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Role of physical activity in cancer prevention: An update.World journal of clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dixita Joshi *Division of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Janaki Patel *Division of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Muskaan MunshiDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Zeel MistryDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Alok PrajapatiDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Asmi MukherjeeDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
A V RamachandranDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Nidarshana Chaturvedi ParasharDepartment of Bio-Sciences and Technology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India. nidarshanachaturvedi@gmail.com.
Gaurav ParasharDivision of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India. parashar_panchal@yahoo.co.in.
Shafiul HaqueResearch and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, 45142, Jazan, Saudi Arabia.
Hardeep Singh TuliDepartment of Bio-Sciences and Technology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a significant cause of mortality in the world, with increasing prevalence worldwide. There are numerous treatments ranging from surgery to chemotherapy and radiotherapy, but since cancer is a heterogeneous disease, only few patients possibly respond to treatments. However, it opens a huge space for the advent of targeted therapies such as hormone therapy, immunotherapy, and target-specific drugs. Hormonal therapy using hormone agonists/antagonists or hormone receptor inhibitors-called the next-generation hormonal agents-hits distinct hormonal pathways that are involved in breast, prostate and ovarian cancer. Preliminary results show that through combination of drugs, it is possible that the synergistic effects may actually lead to better survival than with the use of single drugs. With manageable adverse effects, hormonal therapy offers much hope for treatment of this rather challenging malignancy of the hormone-sensitive cancers, especially in combination with other treatments.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsDisease ProgressionFemaleHormonesHumansMaleMolecular Targeted TherapyNeoplasmsProstatic NeoplasmsAntineoplastic Agents, HormonalHormonesBreast cancerEstrogenHormonal therapyProgesteroneProstate cancerSynergistic effect

Identifiers

PMID39400627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.